Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2003 Jun;55(6):635-8.
doi: 10.1046/j.1365-2125.2003.01805.x.

Polymorphic hydroxylation of perhexiline in vitro

L B Sørensen  1 , R N Sørensen, J O Miners, A A Somogyi, N Grgurinovich, D J Birkett
Affiliations

Polymorphic hydroxylation of perhexiline in vitro

L B Sørensen et al. Br J Clin Pharmacol. 2003 Jun.

Abstract

Aims: The aims of this study were to examine the in vitro enzyme kinetics and CYP isoform selectivity of perhexiline monohydroxylation using human liver microsomes.

Methods: Conversion of rac-perhexiline to monohydroxyperhexiline by human liver microsomes was assessed using a high-performance liquid chromatography assay with precolumn derivatization to measure the formation rate of the product. Isoform selective inhibitors were used to define the CYP isoform profile of perhexiline monohydroxylation.

Results: The rate of perhexiline monohydroxylation with microsomes from 20 livers varied 50-fold. The activity in 18 phenotypic perhexiline extensive metabolizer (PEM) livers varied about five-fold. The apparent Km was 3.3 +/- 1.5 micro m, the Vmax was 9.1 +/- 3.1 pmol min-1 mg-1 microsomal protein and the in vitro intrinsic clearance (Vmax/Km) was 2.9 +/- 0.5 micro l min-1 mg-1 microsomal protein in the extensive metabolizer livers. The corresponding values in the poor metabolizer livers were: apparent Km 124 +/- 141 micro m; Vmax 1.4 +/- 0.6 pmol min-1 mg-1 microsomal protein; and intrinsic clearance 0.026 micro l min-1 mg-1 microsomal protein. Quinidine almost completely inhibited perhexiline monohydroxylation activity, but inhibitors selective for other CYP isoforms had little effect.

Conclusions: Perhexiline monohydroxylation is almost exclusively catalysed by CYP2D6 with activities being about 100-fold lower in CYP2D6 poor metabolizers than in extensive metabolizers. The in vitro data predict the in vivo saturable metabolism and pharmacogenetics of perhexiline.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Effect of CYP isoform selective inhibitors on perhexiline monohydroxylation with three phenotypic perhexiline extensive metabolizer livers. The perhexiline concentration was 5 µm. The inhibitor concentrations and incubation conditions are given in Methods and the values are the means of duplicate determinations.formula image, H12; □, H25; formula image, H27.
Figure 2
Figure 2
Kinetic plots for perhexiline monohydroxylation with (a) two phenotypic perhexiline extensive metabolizer livers (H25 and H27) and (b) two phenotypic perhexiline poor metabolizer livers (H8 and H30). The solid lines are those fitted to the data by nonlinear regression analysis. The data points are the mean of duplicate determinations.
See this image and copyright information in PMC

References

    1. Beaugrand M, Poupon R, Levy VG, Callard P, Lageron A, Lecomte D, et al. Hepatic lesions due to perhexiline maleate. Gastroenterol Clin Biol. 1978;2:579–588. - PubMed
    1. Pessayre D, Bichara M, Degott C, Potet F, Benhamou JP, Feldmann G. Perhexiline maleate-induced cirrhosis. Gastroenterology. 1979;76:170–177. - PubMed
    1. Forbes GB, Rake MO, Taylor DJ. Liver damage due to perhexiline maleate. J Clin Pathol. 1979;32:1282–1285. - PMC - PubMed
    1. Hay DR, Gwynne JF. Cirrhosis of the liver following therapy with perhexiline maleate. NZ Med J. 1983;96:202–204. - PubMed
    1. Paliard P, Vitrey D, Fournier G, Belhadjali J, Patricot L, Berger F. Perhexiline maleate-induced hepatitis. Digestion. 1978;17:419–427. - PubMed

Publication types